湖北能特科技股份有限公司 2025年度业绩预告

Core Viewpoint - The company expects to turn a profit in 2025, with projected net profit ranging from RMB 20 million to 25 million, and net profit excluding non-recurring gains and losses estimated between RMB 32 million and 39 million [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The forecast indicates a positive net profit, marking a turnaround from previous losses [4]. Group 2: Reasons for Performance Changes - The significant growth in the vitamin E business is expected to contribute no less than RMB 660 million to profits, driving substantial year-on-year growth in 2025 [5]. - The pharmaceutical intermediates business underperformed expectations, with lower-than-expected sales of Montelukast sodium intermediates and ongoing intense competition leading to reduced profits from Rosuvastatin intermediates [5]. - The company plans to recognize goodwill impairment of up to RMB 26 million due to the underperformance in the pharmaceutical intermediates sector [5]. - The sale of a wholly-owned subsidiary, Shaanxi Ankang Shenqian Mining Co., Ltd., is projected to reduce profits by RMB 48.87 million as part of a strategy to optimize resource allocation [5]. - Legal provisions are expected to decrease 2025 profits by RMB 79.59 million, categorized as non-recurring losses [6].